Drug Repurposing and Observational Studies: The Case of Antivirals for the Treatment of COVID-19
Annals of Internal Medicine · 2023-04 · 176 (4) · 556-560
DOI: 10.7326/m22-3582 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Internal Medicine, 2023-04. Verfasst von Miguel A Hernán und 1 weiteren Autor:innen. Beteiligte Einrichtung: CAUSALab and Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts (M.A.H.). Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CAUSALab and Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts (M.A.H.).
- Division of HIV, STI, Hepatitis and Tuberculosis, Ministry of Health, Madrid, Spain (J.del A.).
ORCID-Profile: Miguel A Hernán
Förderung
- NIAID NIH HHS
- National Institutes of Health
Zitieren
APA
Hernán, M. A., & Del Amo, J. (2023). Drug Repurposing and Observational Studies: The Case of Antivirals for the Treatment of COVID-19. Annals of Internal Medicine, 176(4), 556-560. https://doi.org/10.7326/m22-3582
Vancouver
Hernán MA, Del Amo J. Drug Repurposing and Observational Studies: The Case of Antivirals for the Treatment of COVID-19. Annals of Internal Medicine. 2023;176(4):556-560. doi:10.7326/m22-3582
BibTeX
@article{Hernn2023,
author = {Hernán, Miguel A and Del Amo, Julia},
title = {Drug Repurposing and Observational Studies: The Case of Antivirals for the Treatment of COVID-19},
journal = {Annals of Internal Medicine},
year = {2023},
volume = {176},
number = {4},
pages = {556--560},
doi = {10.7326/m22-3582}
}
EUVIMED